Article
Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic Markers.
Psychopharmacology bulletin - 1 Jan 2025
Skryabin VYu, Petukhov A E, Pozdniakov S A, Ivanchenko V A, Zaytsev I A, Miroshkin S S, Sokolova S I, Bure I V, Smirnov V V, Sychev D A
Abstract excerpt
Introduction: Alcoholic hallucinosis (AH) is one of the severe complications of chronic alcoholism, characterized by psychotic symptoms such as auditory hallucinations and delusions. Haloperidol is widely used to treat AH; however, its therapy is often complicated by side effects. A personalized approach using pharmacogenetic testing (particularly the CYP2D6 polymorphism) allows individualization of haloperidol...
Topics
Join the communities discussing this publication.